GENFIT (GNFT)
(Delayed Data from NSDQ)
$4.15 USD
-0.06 (-1.31%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $4.16 +0.01 (0.24%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.15 USD
-0.06 (-1.31%)
Updated Jul 24, 2024 03:59 PM ET
After-Market: $4.16 +0.01 (0.24%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock
by Zacks Equity Research
GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60%
by Zacks Equity Research
The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intercept (ICPT) Posts New Positive Results on NASH Drug
by Zacks Equity Research
Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.
Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.
Intercept Slumps as the FDA Issues CRL to NASH Candidate
by Zacks Equity Research
Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Is Genfit (GNFT) Stock a Solid Choice Right Now
by Zacks Equity Research
Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Intercept Down on Postponement of AdCom Meet for NASH Drug
by Zacks.com
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.
Why Genfit (GNFT) Stock Might be a Great Pick
by Zacks Equity Research
Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Genfit Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genfit.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.
Zacks.com featured highlights include: Teledyne, Genfit, Shoe Carnival, ZTO and GCI
by Zacks Equity Research
Zacks.com featured highlights include: Teledyne, Genfit, Shoe Carnival, ZTO and GCI
5 Stocks to Buy on New Analyst Coverage
by Shrabana Mukherjee
Higher analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Top Ranked Momentum Stocks to Buy for April 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 25th
Gilead to Collaborate with Novo Nordisk for NASH Treatment
by Zacks Equity Research
Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.